Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions.

Tytuł:
PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions.
Autorzy:
Unterrainer M; Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. .
Ruzicka M; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Fabritius MP; Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Mittlmeier LM; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Winkelmann M; Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Rübenthaler J; Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Brendel M; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Subklewe M; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
von Bergwelt-Baildon M; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Ricke J; Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Kunz WG; Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Cyran CC; Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.; DIE RADIOLOGIE, Munich, Germany.
Źródło:
European radiology experimental [Eur Radiol Exp] 2020 Nov 17; Vol. 4 (1), pp. 63. Date of Electronic Publication: 2020 Nov 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
Język:
English
Imprint Name(s):
Original Publication: [London, United Kingdom] : SpringerOpen, [2017]-
MeSH Terms:
Positron Emission Tomography Computed Tomography*
Immunotherapy/*methods
Neoplasms/*diagnostic imaging
Neoplasms/*drug therapy
Forecasting ; Humans ; Immunotherapy/adverse effects ; Response Evaluation Criteria in Solid Tumors
References:
Lancet Oncol. 2015 Apr;16(4):375-84. (PMID: 25795410)
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):238-250. (PMID: 30291373)
ESMO Open. 2018 Jan 13;3(1):e000278. (PMID: 29387476)
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):386-96. (PMID: 25359635)
Int J Mol Sci. 2019 May 30;20(11):. (PMID: 31151303)
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29. (PMID: 29796651)
J Clin Oncol. 2015 Nov 1;33(31):3541-3. (PMID: 26261262)
J Clin Oncol. 2018 May 10;36(14):1428-1439. (PMID: 29584546)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Eur J Cancer. 1999 Dec;35(13):1773-82. (PMID: 10673991)
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762. (PMID: 30361681)
Cancer Res. 2017 May 1;77(9):2318-2327. (PMID: 28461564)
JAMA Oncol. 2016 Oct 1;2(10):1346-1353. (PMID: 27367787)
Clin Cancer Res. 2016 Sep 15;22(18):4550-5. (PMID: 27435397)
Immunol Res. 2014 Aug;59(1-3):203-10. (PMID: 24906530)
Cancer Sci. 2017 May;108(5):1007-1012. (PMID: 28267244)
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1158-1167. (PMID: 31760467)
Cancers (Basel). 2020 Jan 03;12(1):. (PMID: 31947775)
Leuk Lymphoma. 2009 Aug;50(8):1257-60. (PMID: 19544140)
Invest New Drugs. 2018 Aug;36(4):638-646. (PMID: 29159766)
Leuk Lymphoma. 2019 Feb;60(2):367-375. (PMID: 30032683)
Oncotarget. 2018 Jul 13;9(54):30268-30278. (PMID: 30100988)
Blood. 1970 Jun;35(6):741-50. (PMID: 4913404)
Front Immunol. 2015 Jul 27;6:368. (PMID: 26284063)
Pigment Cell Melanoma Res. 2016 Sep;29(5):572-7. (PMID: 27333363)
J Clin Oncol. 1999 Apr;17(4):1244. (PMID: 10561185)
Nat Med. 2018 May;24(5):539-540. (PMID: 29736024)
Clin Immunol. 2014 Dec;155(2):160-75. (PMID: 25444722)
J Nucl Med. 2020 May;61(5):649-654. (PMID: 31628220)
J Clin Oncol. 2014 Sep 20;32(27):3059-68. (PMID: 25113753)
Leukemia. 2003 May;17(5):900-9. (PMID: 12750704)
J Hematol Oncol. 2020 Jan 3;13(1):1. (PMID: 31900191)
Semin Nucl Med. 2009 Sep;39(5):308-40. (PMID: 19646557)
Blood. 2016 Nov 24;128(21):2489-2496. (PMID: 27574190)
Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2310-2325. (PMID: 28815334)
Radiology. 2019 Jan;290(1):9-22. (PMID: 30457485)
Nat Commun. 2018 Nov 7;9(1):4664. (PMID: 30405135)
N Engl J Med. 2020 Feb 6;382(6):545-553. (PMID: 32023374)
Ann Hematol. 2017 Apr;96(4):647-651. (PMID: 28138786)
J Nucl Med. 2009 May;50 Suppl 1:122S-50S. (PMID: 19403881)
J Thorac Oncol. 2018 Nov;13(11):1733-1742. (PMID: 29775807)
Annu Rev Immunol. 2001;19:565-94. (PMID: 11244047)
Nat Med. 2018 Jan;24(1):20-28. (PMID: 29155426)
Mol Imaging Biol. 2017 Dec;19(6):903-914. (PMID: 28247187)
Oncologist. 2017 Apr;22(4):470-479. (PMID: 28275115)
Biologics. 2020 Feb 14;14:23-34. (PMID: 32103893)
Cell. 2020 Apr 2;181(1):46-62. (PMID: 32243795)
Bioconjug Chem. 2015 Oct 21;26(10):2062-9. (PMID: 26307602)
Eur J Cancer. 2016 Jul;62:132-7. (PMID: 27189322)
J Clin Invest. 2020 Apr 1;130(4):1586-1594. (PMID: 32235098)
J Clin Oncol. 2007 Feb 10;25(5):579-86. (PMID: 17242396)
Cancer Res. 2018 Oct 1;78(19):5706-5717. (PMID: 30115693)
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289-1296. (PMID: 29478079)
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):376-383. (PMID: 29124281)
Immunol Lett. 2019 Jul;211:13-22. (PMID: 31091431)
Ann Oncol. 2017 Jul 1;28(7):1605-1611. (PMID: 28419181)
Radiology. 2020 Jun;295(3):651-661. (PMID: 32286191)
J Clin Invest. 2019 Mar 21;129(6):2210-2221. (PMID: 30896447)
J Clin Oncol. 2017 Jul 1;35(19):2125-2132. (PMID: 28441111)
Front Oncol. 2019 Mar 26;9:176. (PMID: 30984613)
Biol Blood Marrow Transplant. 2019 Jun;25(6):1092-1098. (PMID: 30769193)
Clin Cancer Res. 2009 Dec 1;15(23):7412-20. (PMID: 19934295)
N Engl J Med. 2019 Jan 3;380(1):45-56. (PMID: 30501490)
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. (PMID: 27827313)
J Immunother Cancer. 2020 Aug;8(2):. (PMID: 32753543)
Front Immunol. 2020 Mar 05;11:176. (PMID: 32194541)
Lancet Oncol. 2017 Mar;18(3):e143-e152. (PMID: 28271869)
J Nucl Med. 2018 Jan;59(1):15-24. (PMID: 28596157)
Nat Med. 2018 Dec;24(12):1852-1858. (PMID: 30478423)
N Engl J Med. 2019 May 2;380(18):1726-1737. (PMID: 31042825)
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. (PMID: 10655437)
J Clin Invest. 2013 Dec;123(12):5098-103. (PMID: 24177426)
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. (PMID: 28925994)
Clin Cancer Res. 2020 Aug 15;26(16):4414-4425. (PMID: 32253232)
Cancer Res Treat. 2018 Oct;50(4):1462-1466. (PMID: 29397660)
J Immunother Cancer. 2016 Sep 20;4:58. (PMID: 27660712)
Cancer Res. 2019 Jan 15;79(2):387-396. (PMID: 30482775)
J Nucl Med. 2017 Sep;58(9):1421-1428. (PMID: 28360208)
Acad Radiol. 2017 Jan;24(1):111-115. (PMID: 27818005)
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):56-66. (PMID: 28828507)
Ann Oncol. 2017 Oct 1;28(10):2377-2385. (PMID: 28945858)
Ann Oncol. 2017 Jul 1;28(7):1436-1447. (PMID: 28379322)
J Clin Invest. 2014 Feb;124(2):812-23. (PMID: 24430180)
N Engl J Med. 2017 Dec 28;377(26):2531-2544. (PMID: 29226797)
Eur J Cancer. 2018 Mar;91:136-144. (PMID: 29360605)
Blood. 2016 Jun 30;127(26):3321-30. (PMID: 27207799)
Cytotherapy. 2018 Dec;20(12):1415-1418. (PMID: 30385043)
J Clin Oncol. 2016 Nov 1;34(31):3733-3739. (PMID: 27354476)
Nat Rev Immunol. 2018 Mar;18(3):153-167. (PMID: 28990585)
PET Clin. 2020 Jan;15(1):35-43. (PMID: 31735300)
Am J Hematol. 2018 Jun 8;:. (PMID: 29884994)
Clin Nucl Med. 2019 Apr;44(4):e272-e279. (PMID: 30688730)
N Engl J Med. 2015 Jan 22;372(4):311-9. (PMID: 25482239)
JAMA Oncol. 2018 Mar 1;4(3):374-378. (PMID: 28975219)
Contributed Indexing:
Keywords: Antigens (neoplasm); Fluorodeoxyglucose F18; Immunotherapy; Positron emission tomography computed tomography; Receptors (chimeric antigen)
Entry Date(s):
Date Created: 20201117 Date Completed: 20210705 Latest Revision: 20210705
Update Code:
20240105
PubMed Central ID:
PMC7669926
DOI:
10.1186/s41747-020-00190-1
PMID:
33200246
Czasopismo naukowe
Recent immunotherapeutic approaches have evolved as powerful treatment options with high anti-tumour responses involving the patient's own immune system. Passive immunotherapy applies agents that enhance existing anti-tumour responses, such as antibodies against immune checkpoints. Active immunotherapy uses agents that direct the immune system to attack tumour cells by targeting tumour antigens. Active cellular-based therapies are on the rise, most notably chimeric antigen receptor T cell therapy, which redirects patient-derived T cells against tumour antigens. Approved treatments are available for a variety of solid malignancies including melanoma, lung cancer and haematologic diseases. These novel immune-related therapeutic approaches can be accompanied by new patterns of response and progression and immune-related side-effects that challenge established imaging-based response assessment criteria, such as Response Evaluation Criteria in Solid tumours (RECIST) 1.1. Hence, new criteria have been developed. Beyond morphological information of computed tomography (CT) and magnetic resonance imaging, positron emission tomography (PET) emerges as a comprehensive imaging modality by assessing (patho-)physiological processes such as glucose metabolism, which enables more comprehensive response assessment in oncological patients. We review the current concepts of response assessment to immunotherapy with particular emphasis on hybrid imaging with 18 F-FDG-PET/CT and aims at describing future trends of immunotherapy and additional aspects of molecular imaging within the field of immunotherapy.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies